Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
$29.68
-$0.51(-1.26%)
At close: 4:00 PM EST
$29.68
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$22.71 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)3.37M
Market Cap
$2.76B
Enterprise Value$3.76B
Total Cash (Recent Filing)$295.01M
Total Debt (Recent Filing)$61.53M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 14, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding96,127,266
10 Day Avg. Volume4,276,633
30 Day Avg. Volume3,374,511
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.63K
Enterprise Value/Ebitda-11.79
Forecast
1Y Price Target
$47.70Price Target Upside60.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyApitegromab is the first myostatin-targeting therapy to show a statistically significant benefit in motor function in a pivotal trial.
Financial StabilityScholar Rock's balance sheet is strong with $295M cash, $60M in warrants, and $50M debt capacity, sufficient to bridge into approval even under a Class II review.
Market PotentialThere is a significant market opportunity for apitegromab in SMA, with risk-adjusted peak sales modeled at $2bn in 2037.
Bears Say
Approval DelaysSRRK's third-party fill-finish manufacturer received an Official Action Indicated (OAI) classification by FDA, suggesting a re-inspection will likely be required before the drug can receive approval.
Market VolatilityScholar Rock's shares are expected to remain volatile and very sensitive to any additional headlines or disclosures in the near term.
Regulatory ChallengesThe Catalent Indiana facility, acquired by Novo Nordisk, received an Official Action Indicated (OAI) classification, which is seen as a net negative for near-term approval prospects for Scholar Rock's apitegromab.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $22.71 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $2.76B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Nov 14, 2025 which is in 19 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Aug 06, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.665 by -$0.315.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 96,127,266 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.665. Following the earnings report the stock price went down -6.382%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.70 (60.71% Upside)
$47.70 (60.71% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $18.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 42.5%
Last 30 Days ▲ 42.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.30%
12-Months-Change
Fundamentals
Return on Equity
-172.08%
Trailing 12-Months
Asset Growth
49.89%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation is a biotechnology company specializing in the discovery and development of innovative medicines for the treatment of serious diseases in which protein growth factors play a fundamental role. The company focuses on addressing unmet medical needs in areas such as neuromuscular disorders, cancer, fibrosis, and anemia, employing its proprietary platform to target latent forms of growth factors and modulate their activity.
SRRK Company Deck
SRRK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive outlook with significant regulatory and commercial progress for apitegromab, supported by strong financials and positive clinical trial results. However, there are challenges due to FDA observations at CDMO sites. While these issues pose potential risks, the company's preparedness and strategic initiatives provide confidence in overcoming these hurdles.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$47.70
▲(60.71% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
23.39% Insiders
32.45% Mutual Funds
0.08% Other Institutional Investors
32.83% Public Companies and
Individual Investors